Literature DB >> 25981371

Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy.

Beat A Kaufmann1, Kaatje Goetschalckx2, Son Y Min3, Micha T Maeder4, Urs Bucher3, Fabian Nietlispach5, Alain M Bernheim6, Matthias E Pfisterer3, Hans-Peter Brunner-La Rocca7.   

Abstract

BACKGROUND: In chronic heart failure, left ventricular ejection fraction (LVEF) is considered to be stable. Intensified therapy may improve survival, but little is known whether this is associated with reverse remodeling and dependent on age and NT-proBNP guidance. We aimed to define the evolution of LVEF under intensified therapy in relation to age and NT-proBNP guidance. METHODS AND
RESULTS: Echocardiography was performed at baseline, 12 and 18months in TIME-CHF, a trial comparing NT-proBNP versus symptom-guided therapy in patients aged 60 to 74 and ≥75 years. LVEF, LV end diastolic volume index (LVEDVI) and end systolic volume index (LVESVI) were assessed. LVEF increased from 31.3 ± 10.7% to 39.1±11.8% at 18 months (p<0.001) in symptom-guided, and from 30.3 ± 11.7% to 44.0 ± 13.2% (p<0.001) in NT-proBNP-guided patients. The increase in LVEF was significantly larger in the NT-proBNP-guided treatment group (p for interaction=0.006), which was true for both age groups (p for interaction in both=0.091). LVEDVI and LVESVI decreased without influence by study group allocation.
CONCLUSIONS: In elderly heart failure patients, intensified medical therapy leads to an improvement in LVEF and to reverse remodeling. NT-proBNP guided therapy was associated with a larger improvement in LVEF than symptom guided therapy both in patients aged 60 to 74 and ≥75 years. TRIAL REGISTRATION: http://isrctn.org Identifier: ISRCTN43596477.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Heart failure; Left ventricular ejection fraction; Outcome

Mesh:

Substances:

Year:  2015        PMID: 25981371     DOI: 10.1016/j.ijcard.2015.04.282

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Biomarker Guided Therapy in Chronic Heart Failure.

Authors:  Hans-Peter Brunner-La Rocca; Sema Bektas
Journal:  Card Fail Rev       Date:  2015-10

Review 2.  B-type natriuretic peptide-guided treatment for heart failure.

Authors:  Julie McLellan; Carl J Heneghan; Rafael Perera; Alison M Clements; Paul P Glasziou; Karen E Kearley; Nicola Pidduck; Nia W Roberts; Sally Tyndel; F Lucy Wright; Clare Bankhead
Journal:  Cochrane Database Syst Rev       Date:  2016-12-22

3.  The minimal informative monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure.

Authors:  Zhehao Dai; Taku Asano; Osamu Takahashi; Nobuyuki Komiyama; Sachiko Ohde
Journal:  BMC Cardiovasc Disord       Date:  2020-06-01       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.